KRM Ayurveda LimitedQ1 FY27 Results & Financial Update
KRM Ayurveda Limited: Q1 FY27 standalone results and company financials – revenue ₹32.32 Cr, PAT ₹9.08 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
KRM Ayurveda price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore KRM Ayurveda Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
KRM Ayurveda Limited delivered a strong financial performance for the quarter ended June 30, 2026, reporting revenue from operations of INR 32.32 crore and a total income of INR 32.87 crore.
Profitability expanded significantly during the period, driven by operating leverage and disciplined expense management. Profit Before Tax reached INR 12.23 crore, while Net Profit (PAT) stood at INR 9.08 crore, translating to a basic EPS of INR 4.27.
Operating profitability improved notably, with EBITDA reaching INR 12.56 crore and the EBITDA margin strengthening to 38.22 percent, marking a high across recent quarters. PAT margin stood at 27.64 percent for the quarter.
The hospital and services division served as the primary growth engine, underpinned by capacity expansion and the ongoing maturation of recently added healthcare facilities.
Total expenses for the quarter were contained at INR 20.63 crore, reflecting operational efficiency as the business scales its infrastructure and patient intake.
Other income contributed INR 0.54 crore to the top line, while finance costs and depreciation remained modest at INR 0.06 crore and INR 0.26 crore respectively.
Profit after tax was ₹9.08 Cr for the reported quarter. EPS was ₹4.27 for the reported quarter.
01 · Business model
What does KRM Ayurveda do?
KRM Ayurveda Limited operates in the integrated healthcare and wellness sector, focusing on traditional Ayurvedic treatments, hospital services, and specialized therapeutic care.
The company generates revenue streams through its expanding network of hospitals and clinics alongside an established product business spanning capsules, tablets, syrups, oils, and disease-specific wellness kits.
Manufacturing operations are anchored by an in-house GMP and ISO certified supply facility located at Kundli, Haryana, which supports both institutional requirements and retail distribution.
Strategic expansion leverages targeted catchment selections where existing brand equity and physician networks facilitate rapid asset utilisation and shorter operational maturity curves.
02 · Historical context
What shaped the business before this quarter
Product revenue remained broadly stable at INR 47.01 crore in FY26 compared to INR 49.23 crore in FY25.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹32.32 Cr |
| Total income | ₹32.87 Cr |
| Profit before tax | ₹12.23 Cr |
| Profit after tax | ₹9.08 Cr |
| EPS | ₹4.27 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Services revenue for Q1 FY27 grew substantially to INR 23.92 crore, up 109.8 percent year-on-year and 45.6 percent sequentially, driven by new facility ramp-ups and bed additions.
Product revenue stood at INR 8.40 crore for Q1 FY27, reflecting normal quarterly phasing following the higher seasonal demand observed in Q4 FY26.
Other income increased to INR 0.54 crore for the quarter, higher than both the same quarter last year and the preceding quarter.
What drove margins
EBITDA margin expanded to 38.22 percent in Q1 FY27, supported by efficient fixed-cost absorption as new hospital beds and services gained utilisation.
Total expenses of INR 20.63 crore grew at a slower pace relative to revenue expansion, helping drive PAT margin up to 27.64 percent.
05 · Demand, customers & order book
Where demand is coming from
The company commands an owned digital audience of over 8 lakh followers across three YouTube channels, providing a warm start for upcoming direct-to-consumer initiatives.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Services revenue demonstrated strong momentum, scaling to INR 23.92 crore in Q1 FY27 from INR 11.40 crore in Q1 FY26.
The product portfolio continues to manufacture and distribute capsules, tablets, syrups, and wellness kits from the Kundli manufacturing facility.
Geography and market mix
New facilities are opened selectively in catchments capable of supporting rapid utilisation build-up, aided by existing brand pull and physician networks.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company added 2 hospitals, 1 clinic, and 103 beds during the current financial year to date.
New facilities target a utilisation ramp of 60 percent between months 2-4, advancing to 80 percent by months 6-8.
Projects, capex and execution
Incremental annualised IPD revenue potential from the 103 beds added till date in FY27 is estimated at approximately INR 25 crore.
08 · Strategy & new businesses
How the company is trying to change its growth mix
An owned direct-to-consumer e-commerce storefront is scheduled to go live in Q2 FY27 to sell directly to patients and reduce marketing expenses.
Listings on 1mg and other leading national marketplaces are planned for Q2 FY27 to extend reach beyond current operating territories.
09 · Reported developments
What changed operationally
EBITDA doubled year-on-year to INR 12.56 crore, while Net Profit surged to INR 9.08 crore.
Addition of 103 beds and new hospital units positions the company to capture incremental annualised IPD revenue potential of around INR 25 crore.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Digital and D2C Strategy
The upcoming launch of the owned D2C platform and marketplace integrations in Q2 FY27 is expected to smooth out quarterly phasing volatility associated with bulk ordering.
11 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations remained steady at INR 32.32 crore compared to INR 32.21 crore in Q4 FY26, while EBITDA increased 12.4 percent sequentially from INR 11.18 crore.
12 · Key Q&A
The quarter, answered directly
What does KRM Ayurveda do?
KRM Ayurveda Limited operates in the integrated healthcare and wellness sector, focusing on traditional Ayurvedic treatments, hospital services, and specialized therapeutic care.
What is the clearest takeaway from Q1 FY27?
KRM Ayurveda Limited delivered a strong financial performance for the quarter ended June 30, 2026, reporting revenue from operations of INR 32.32 crore and a total income of INR 32.87 crore.
What drove revenue or demand?
Services revenue for Q1 FY27 grew substantially to INR 23.92 crore, up 109.8 percent year-on-year and 45.6 percent sequentially, driven by new facility ramp-ups and bed additions.
What mattered most for margins or profitability?
EBITDA margin expanded to 38.22 percent in Q1 FY27, supported by efficient fixed-cost absorption as new hospital beds and services gained utilisation.
What changed operationally beyond the headline numbers?
The company added 2 hospitals, 1 clinic, and 103 beds during the current financial year to date.
What should the next disclosure help confirm?
Execution and customer adoption of the owned e-commerce storefront and marketplace listings scheduled for Q2 FY27.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
D2C Platform Rollout: Execution and customer adoption of the owned e-commerce storefront and marketplace listings scheduled for Q2 FY27.
- 02
Facility Ramp-Up: Utilisation progression of the 103 newly added beds towards targeted maturity thresholds.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.